UK Antibody Drug Conjugates Market Size & Outlook
Related Markets
UK antibody drug conjugates market highlights
- The UK antibody drug conjugates market generated a revenue of USD 190.5 million in 2021 and is expected to reach USD 887.7 million by 2030.
- The UK market is expected to grow at a CAGR of 18.6% from 2022 to 2030.
- In terms of segment, breast cancer was the largest revenue generating application in 2021.
- Blood Cancer is the most lucrative application segment registering the fastest growth during the forecast period.
Antibody drug conjugates market data book summary
| Market revenue in 2021 | USD 190.5 million |
| Market revenue in 2030 | USD 887.7 million |
| Growth rate | 18.6% (CAGR from 2021 to 2030) |
| Largest segment | Breast cancer |
| Fastest growing segment | Blood Cancer |
| Historical data | 2018 - 2020 |
| Base year | 2021 |
| Forecast period | 2022 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Blood Cancer, Breast Cancer |
| Key market players worldwide | Pfizer Inc, Takeda Pharmaceutical Co Ltd, AstraZeneca PLC, Roche Holding AG, Gilead Sciences Inc, Daiichi Sankyo Co Ltd, GlaxoSmithKline Consumer Healthcare (GSK CH India), Astellas Pharma Inc, ADC Therapeutics SA |
Other key industry trends
- In terms of revenue, UK accounted for 3.3% of the global antibody drug conjugates market in 2021.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany antibody drug conjugates market is projected to lead the regional market in terms of revenue in 2030.
- Italy is the fastest growing regional market in Europe and is projected to reach USD 758.8 million by 2030.
Breast cancer was the largest segment with a revenue share of 67.61% in 2021. Horizon Databook has segmented the UK antibody drug conjugates market based on blood cancer, breast cancer covering the revenue growth of each sub-segment from 2018 to 2030.
The UK is expected to witness significant growth in Europe over the forecast period, owing to factors such as increasing R&D efforts on ADCs for cancer and improving accessibility of targeted drugs. For instance, UK-based companies Glythera now Iksuda Therapeutics and IONTAS are co-developing next-gen ADC drugs for difficult-totreat tumors.
In 2017, Glythera (now Iskuda Therapeutics) received USD 1.29 million from Innovate UK for development of ADCs. Thus, increasing funding from public and private entities is expected to boost the development of ADCs.
In 2017, Roche and NHS England partnered up to improve accessibility of breast cancer drug, Kadcyla, for regular use. Moreover, in May 2020, Kadycla was further approved by the National Institute of Health and Care Excellence in the UK to be used as an adjuvant for the treatment of patients with HER2-positive early breast cancer.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antibody Drug Conjugates Market Scope
Antibody Drug Conjugates Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
UK antibody drug conjugates market size, by application, 2018-2030 (US$M)
UK Antibody Drug Conjugates Market Outlook Share, 2021 & 2030 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
